Atossa Therapeutics, Inc. ATOS
Biotechnology: Pharmaceutical Preparations · IPO 2012 · data as of November 13, 2026
Atossa Therapeutics, Inc. (ATOS) is a healthcare company listed in the US with a market value of about $20M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -41%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
About Atossa Therapeutics
Atossa Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2012. It was profitable in 0 of the last 10 years in our data. Its share count rose by 2% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$35M | -$26M | -$30M | -$27M | -$21M | -$18M | -$17M | -$11M | -$8M | -$6M |
| Free cash flow | -$30M | -$21M | -$21M | -$21M | -$16M | -$12M | -$9M | -$9M | — | — |
| EPS (diluted) | $-4.04 | $-3.04 | $-3.60 | $-3.15 | $-2.70 | $-29.55 | $-30448.74 | $-82496.59 | $-164543.20 | $-388783.83 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -94.4% | -38.6% | -34.5% | -23.5% | -14.9% | -53.7% | -130.7% | -128.4% | -110.2% | -203.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Atossa Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Atossa Therapeutics pay a dividend?
Not currently.
Is Atossa Therapeutics a good stock to buy?
We do not give buy or sell advice. Atossa Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.